SEC Form SC 13G/A filed by Akari Therapeutics plc (Amendment)

$AKTX
Biotechnology: Pharmaceutical Preparations
Health Care
Get the next $AKTX alert in real time by email
SC 13G/A 1 ea173418-13ga4patel_akari.htm AMENDMENT NO. 4 TO SCHEDULE 13G

 

 

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

 

SCHEDULE 13G

 

Under the Securities Exchange Act of 1934

(Amendment No. 4)*

 

 

 

Akari Therapeutics, PLC

(Name of Issuer)

 

Ordinary Shares, par value $0.0001 per share

(represented by American Depositary Shares)

(Title of Class of Securities)

 

00972G108

(CUSIP Number)

 

December 31, 2022

(Date of Event which Requires Filing of this Statement)

 

 

 

Check the appropriate box to designate the rule pursuant to which this schedule is filed:

 

Rule 13d-1(b)

 

Rule 13d-1(c)

 

Rule 13d-1(d)

 

*The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

 

The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

 

 

 

 

 

 

CUSIP No. 00972G108 SCHEDULE 13G Page 2 of 5

 

1

NAME OF REPORTING PERSON

 

Samir R. Patel

2

CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

 

(a) ☐

(b) ☐

3

SEC USE ONLY

 

4

CITIZENSHIP OR PLACE OF ORGANIZATION

 

United States

NUMBER OF
SHARES

BENEFICIALLY

OWNED BY

EACH
REPORTING PERSON
WITH

5

SOLE VOTING POWER

 

7,862,047 shares(1)

6

SHARED VOTING POWER

 

0 shares

7

SOLE DISPOSITIVE POWER

 

7,862,047 shares(1)

8

SHARED DISPOSITIVE POWER

 

0 shares

9

AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

 

7,862,047 shares(1)

10

CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

 

 ☐

11

PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

 

9.9%

12

TYPE OF REPORTING PERSON

 

IN

 

 

(1)Comprised of Ordinary Shares represented by American Depositary Shares. Each American Depositary Share reported represents 100 Ordinary Shares. Includes warrants to purchase up to 2,238,748 American Depositary Shares. Does not include warrants to purchase up to 2,011,252 American Depositary Shares which are not exercisable within the next 60 days and for which the reporting person disclaims beneficial ownership.

 

 

 

 

CUSIP No. 00972G108 SCHEDULE 13G Page 3 of 5

 

Item 1(a). Name of Issuer

 

Akari Therapeutics, PLC (the “Issuer”)

 

Item 1(b). Address of Issuer’s Principal Executive Offices

 

75/76 Wimpole Street

London W1G 9RT

United Kingdom

 

Item 2(a). Name of Person Filing

 

Samir R. Patel (the “Reporting Person”)

 

Item 2(b). Address of Principal Business Office or, if None, Residence

 

The address of the principal business and principal office of the Reporting Person is:

 

1701 Chicon St., Austin, Texas, 78702

 

Item 2(c). Citizenship

 

Samir R. Patel is a citizen of the United States.

 

Item 2(d). Title of Class of Securities

 

Ordinary Shares, par value $0.0001 per share (represented by American Depositary Shares, each of which represents 100 Ordinary Shares)

 

Item 2(e). CUSIP Number

 

00972G108

 

Item 3. If this statement is filed pursuant to Rule 13d-1(b), or 13d-2(b) or (c), check whether the person filing is a:

 

  (a) Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o).
       
  (b) Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c).
       
  (c) Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c).
       
  (d) Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C 80a-8).
       
  (e) An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E).

 

 

 

 

CUSIP No. 00972G108 SCHEDULE 13G Page 4 of 5

 

  (f) An employee benefit plan or endowment fund in accordance with §240.13d-1(b)(1)(ii)(F).
       
  (g) A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G).
       
  (h) A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813).
       
  (i) A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3).
       
  (j) Group, in accordance with §240.13d-1(b)(1)(ii)(J).

 

Item 4. Ownership

 

With respect to the beneficial ownership of the Reporting Person, see Items 5 through 11 of the cover pages to this Schedule 13G, which are incorporated herein by reference.

 

Item 5. Ownership of Five Percent or Less of a Class.

 

If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following. ☐

 

Item 6. Ownership of More than Five Percent on Behalf of Another Person.

 

Not Applicable.

 

Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company.

 

Not Applicable.

 

Item 8. Identification and Classification of Members of the Group.

 

Not Applicable.

 

Item 9. Notice of Dissolution of Group.

 

Not Applicable.

 

Item 10. Certifications.

 

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under §240.14a-11.

 

 

 

 

CUSIP No. 00972G108 SCHEDULE 13G Page 5 of 5

 

SIGNATURE

 

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

 

Dated: February 14, 2023

 

  /s/ Samir R. Patel
  Samir R. Patel

 

 

 

 

 

 

Get the next $AKTX alert in real time by email

Chat with this insight

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$AKTX

DatePrice TargetRatingAnalyst
More analyst ratings

$AKTX
Press Releases

Fastest customizable press release news feed in the world

See more
  • Akari Therapeutics Appoints Biotechnology Industry Leader, Abizer Gaslightwala, as President and Chief Executive Officer

    Former SVP and Franchise Head for US Oncology at Jazz Pharmaceuticals, with established track record for leading a portfolio of products spanning both solid and hematological malignancies that have total annual sales of $1B Held several executive leadership roles at Amgen, Pfizer, and Johnson & Johnson across multiple brands including Kyprolis®, Vectibix®, Neulasta®, XGEVA®, Repatha®, and ELIQUIS® Current President and CEO, Samir R. Patel, M.D., to remain as a member of the Company's Board of Directors BOSTON and LONDON, March 20, 2025 (GLOBE NEWSWIRE) -- Akari Therapeutics Plc (NASDAQ:AKTX) ("Akari" or the "Company"), a biotechnology company developing next-generation preci

    $AKTX
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • Akari Therapeutics Announces $7.6 Million Private Placement Offering Led by Existing Shareholders and Insiders Priced at the Market Under Nasdaq Rules

    BOSTON and LONDON, March 03, 2025 (GLOBE NEWSWIRE) -- Akari Therapeutics Plc (NASDAQ:AKTX), a biotechnology company developing next-generation precision bi-functional antibody drug conjugates (ADCs) for the treatment of cancer, today announced the successful pricing of a private placement financing round. This transaction is expected to raise an aggregate of approximately $7.6 million in gross proceeds. With these funds the Company will focus on investing in its novel spliceosome inhibitor payload ADC technology platform, seeking license partners for its TROP-2 ADC program, and monetizing non-core assets. "We were very pleased that the private placement was supported by existing investors

    $AKTX
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • Akari Therapeutics Participates in the Virtual Investor "Top 5 for '25" On-Demand Conference

    On-demand video webcast now available here BOSTON and LONDON, Feb. 19, 2025 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (NASDAQ:AKTX), a biotechnology company developing next-generation precision bi-functional antibody drug conjugates (ADC) for the treatment of cancer, today announced it participated in the Virtual Investor "Top 5 for ‘25" On-Demand Conference. As part of the event, Dr. Samir Patel, President and Chief Executive Officer of Akari Therapeutics, presented the top five reasons of why he believes the investment community and industry colleagues should pay attention to Akari in 2025. The on-demand video webcast is now accessible for viewing here and on the Investors section o

    $AKTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

$AKTX
Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

See more

$AKTX
SEC Filings

See more

$AKTX
Leadership Updates

Live Leadership Updates

See more
  • Akari Therapeutics Appoints Biotechnology Industry Leader, Abizer Gaslightwala, as President and Chief Executive Officer

    Former SVP and Franchise Head for US Oncology at Jazz Pharmaceuticals, with established track record for leading a portfolio of products spanning both solid and hematological malignancies that have total annual sales of $1B Held several executive leadership roles at Amgen, Pfizer, and Johnson & Johnson across multiple brands including Kyprolis®, Vectibix®, Neulasta®, XGEVA®, Repatha®, and ELIQUIS® Current President and CEO, Samir R. Patel, M.D., to remain as a member of the Company's Board of Directors BOSTON and LONDON, March 20, 2025 (GLOBE NEWSWIRE) -- Akari Therapeutics Plc (NASDAQ:AKTX) ("Akari" or the "Company"), a biotechnology company developing next-generation preci

    $AKTX
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • Akari Therapeutics Announces Key Leadership Appointments

    Samir R. Patel, M.D., appointed as Chief Executive Officer Abizer Gaslightwala appointed to Board of Directors BOSTON and LONDON, Dec. 18, 2024 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (NASDAQ:AKTX) today announced the appointment of Samir R. Patel, M.D., as Chief Executive Officer, effective December 16, 2024. Dr. Patel has served as interim Chief Executive Officer since May 2024. Additionally, the Company announced it has appointed Abizer Gaslightwala to its Board of Directors, effective December 16, 2024. Michael Grissinger, a member of the Board of Directors, provided notice of his resignation on December 16, 2024. "Since beginning my role as interim CEO in May 2024, we ha

    $AKTX
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • Akari Therapeutics Appoints Torsten Hombeck, Ph.D. as Chief Financial Officer

    BOSTON and LONDON, Dec. 16, 2024 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (NASDAQ:AKTX) today announced the appointment of Torsten Hombeck, Ph.D. as Chief Financial Officer, effective December 16, 2024. Dr. Hombeck is a seasoned executive with over 20 years of experience in the biotechnology industry, finance, capital markets and M&A transactions, as well as clinical and commercial product development and regulatory filings in the U.S. and Europe. "We are pleased with the continued evolution and progress made across multiple fronts. We believe that adding expertise to our leadership team is a key component of ensuring continued progress and importantly our ability to build upon momentu

    $AKTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

$AKTX
Financials

Live finance-specific insights

See more
  • Akari Therapeutics Announces Shareholder Approval in Connection With Peak Bio, Inc. Merger

    BOSTON and LONDON, Nov. 08, 2024 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (NASDAQ:AKTX), an innovative biotechnology company developing advanced therapies for autoimmune and inflammatory diseases, announces shareholder approval in connection with the merger of Akari Therapeutics, Plc (the Company) and Peak Bio, Inc. At a General Meeting held in relation to the merger at 9:00 a.m. Eastern Time on Thursday, November 7, 2024 at the Company's offices in London, shareholders approved the Company's issuance of shares in connection with the proposed merger, with approximately 99% of shares present at the General Meeting, in person or by proxy, voted in support. "I am thrilled to announce this

    $AKTX
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • Akari Therapeutics Announces Effectiveness of Form S-4 and General Meeting Date of November 7, 2024 Related to Peak Bio Merger

    BOSTON and LONDON, Oct. 15, 2024 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (NASDAQ:AKTX), an innovative biotechnology company developing advanced therapies for autoimmune and inflammatory diseases, announces the effectiveness of the Form S-4, originally filed with the SEC on September 13, 2024 related to the merger of Akari Therapeutics, Plc (the Company) and Peak Bio, Inc. The Form S-4 was declared effective by the SEC on October 11, 2024 allowing the Company to definitively schedule the General Meeting to be held in relation to the merger. The General Meeting will be held at 9:00 a.m. Eastern Time on Thursday, November 7, 2024 at the Company's offices in London. "I am so excited to be

    $AKTX
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • Akari Therapeutics Announces Interim CEO Employment Contract Demonstrating Alignment with Shareholders

    Interim CEO employment contract consists solely of equity compensationSamir R. Patel, M.D., increases ownership to 14.2% with $1.25m investment in recent private placement BOSTON and LONDON, June 05, 2024 (GLOBE NEWSWIRE) -- Akari Therapeutics Plc (NASDAQ:AKTX), an innovative biotechnology company advancing therapies for autoimmune and inflammatory diseases, in follow up to the May 1st announcement that Samir R. Patel, M.D., has assumed the role of Interim President & CEO, provides detail of Dr. Patel's employment compensation. Dr Patel's employment contract reaffirms his desire to align his success directly with the success of the company's shareholders. Dr. Patel will be compen

    $AKTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

$AKTX
Large Ownership Changes

This live feed shows all institutional transactions in real time.

See more